Clinical Trials · NCT01885208
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 813
- Start date
- Dec 2013
- Locations
- 146 sites, 13 countries
- Primary endpoint
- Change From Baseline in HbA1c (Glycosylated Haemoglobin)